Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70642 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Curtis Marcoux und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Paula and Rodger Riney Foundation, NCI NIH HHS, MD Anderson Cancer Center.
Abstract (Originalsprache)
Bortezomib, lenalidomide and dexamethasone (VRd) and carfilzomib, lenalidomide and dexamethasone (KRd) regimens have been widely used for induction in transplant‐eligible newly diagnosed multiple myeloma (NDMM), yet direct comparisons between these regimens have been limited and inconsistent. We retrospectively analysed 1129 NDMM patients who received KRd ( n = 364) or VRd ( n = 765) before upfront autologous haematopoietic stem cell transplantation at a single‐centre between 2006 and 2021. KRd‐treated patients more often had high‐risk cytogenetics and advanced Second revision of the International Staging System (R2‐ISS) stage. Pretransplant complete response (CR) and ≥very good partial response (VGPR) rates were higher with KRd (23% and 71%) than VRd (16% and 61%; p = 0.002), with superior best post‐transplant ≥CR (71% vs. 60%; p = 0.001) and higher pretransplant measurable residual disease (MRD) negativity (49% vs. 42%; p = 0.027). After a median follow‐up of 38.6 months, median progression‐free survival (PFS) was 62.2 versus 48.7 months (hazard ratio [95% confidence interval] 0.74 [0.59–0.93], p = 0.009) and median overall survival (OS) was not reached versus 122.7 months (0.86 [0.59–1.25], p = 0.43) for KRd and VRd respectively. In inverse probability–weighted multivariable analysis, KRd remained associated with improved PFS (0.76 [0.60–0.97], p = 0.025), with no OS difference. The PFS benefit was most pronounced in standard‐risk, younger and male patients, and those with fewer comorbidities. Overall, KRd induction led to deeper responses and improved PFS compared with VRd.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Samer Srour, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Hans C Lee, Sheeba K Thomas, Oren Pasvolsky
Förderung
- Paula and Rodger Riney Foundation
- NCI NIH HHS
- MD Anderson Cancer Center
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Leukemia and Lymphoma Society
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Ramdial, J., Nieto, Y., Ahmed, S., Deeba, R. E., Tang, G., Aljawai, Y., Lee, H. C., Patel, K. K., Gaballa, M. R., Kebriaei, P., Thomas, S. K., Orlowski, R. Z., …, & Pasvolsky, O. (2026). Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.70642
Vancouver
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. British Journal of Haematology. 2026. doi:10.1111/bjh.70642
BibTeX
@article{Marcoux2026,
author = {Marcoux, Curtis and Milton, Denái R and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Ramdial, Jeremy and Nieto, Yago and Ahmed, Saqib and Deeba, Rita E and Tang, Guilin and Aljawai, Yosra and Lee, Hans C and Patel, Krina K and Gaballa, Mahmoud R and Kebriaei, Partow and Thomas, Sheeba K and Orlowski, Robert Z and Champlin, Richard E and Shpall, Elizabeth J and Qazilbash, Muzaffar H and Pasvolsky, Oren},
title = {Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70642}
}
EUVIMED